

That is, it appears that a full search for art relevant to the claims of Group II will also yield any art relevant to the claims of Group I.

Additionally, applicants note that the restriction requirement does not deal with the "kit" claims 32-34. As the Official Action is silent with respect to the grouping of those claims, it is believed that the interests of fairness and compact prosecution recommend that those claims be examined together with the elected group.

Item 3 of the Official Action called for submission of a Sequence Listing, and the same is provided herewith. Applicants hereby state that the attached sequence listing does not introduce new matter into this application, and that the attached paper and disk versions of the Sequence Listing contain the same information.

For ease of reference, we note the following correspondence of the Sequence ID numbers, to the present disclosure:

- Figure 1 discloses SEQ ID NOS 1 & 2;
- the spacer sequence listed on page 34 is covered by SEQ ID NO: 3;
- the cyclopeptide listed on pages 41-42 is covered by SEQ ID NO: 4;
- the oligo listed on page 45 is covered by SEQ ID NO: 5;
- the oligo listed on page 46 is covered by SEQ ID NO: 6;
- the oligo listed on page 47 is covered by SEQ ID NO: 7;

- the primers listed on page 54 are covered by SEQ ID NOS 8 & 9;
- the primers listed on page 55 are covered by SEQ ID NOS 10-12;
- the oligo listed on page 56 is covered by SEQ ID NO: 13;
- the oligo listed on page 57 is covered by SEQ ID NO: 14;
- the oligos listed on page 58 are covered by SEQ ID NOS 15-17;
- the oligos listed on page 59 are covered by SEQ ID NOS 18-23; and
- the oligos listed on page 60 are covered by SEQ ID NOS 24 & 25.

An action on the merits of claims 1-28 and 32-34 is now respectfully requested.

Respectfully submitted,

YOUNG & THOMPSON

By   
Andrew J. Patch  
Attorney for Applicants  
Registration No. 32,925  
745 South 23rd Street  
Arlington, VA 22202  
Telephone: 703/521-2297

November 3, 2000